Arena Pharmaceuticals NASDAQ:ARNA is reporting this earnings, what to expect.

0
477

Arena Pharmaceuticals NASDAQ:ARNA is reporting this earnings, what to expect.

Arena Pharmaceuticals NASDAQ:ARNA headquartered in San Diego, California, United States is reporting their earnings on 05/08/2018 before the bell. Street forecast for the quarter ending March 2018 is $-0.7.

According to stock market daily analyst this is Lower then same time previous year. Arena Pharmaceuticals reported EPS for the sARNA quarter last year was $-0.9.

()
()

Chart

Overview of Arena Pharmaceuticals NASDAQ:ARNA

Arena Pharmaceuticals, Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, California.The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas. The company’s most advanced investigational clinical programs are ralinepag (formerly APD811) in testing for pulmonary arterial hypertension (PAH), etrasimod (formerly APD334) in evaluation for inflammatory indications and APD371 for the treatment of pain associated with Crohn’s disease.[4] In 2016 the company downsized and shifted its focus to developing new drugs currently being tested in clinical trials.

ARNA
Change
% Change
Market Cap
% Change from 52 Week Low
% Change from 52 Week High
Shares Outstanding
Volume
Dividend Rate